A Brave New World: Regulatory Flexibility Key To AI Development, Stakeholders Say
Executive Summary
About 130 stakeholders representing a broad spectrum of the health-care industry are asking the US FDA to consider taking a soft touch in any future guidance document addressing artificial intelligence and machine learning devices in order to keep up with developments in the field. Drug lobbyists have also asked the agency to develop guidance that reaches across centers to avoid future conflicts.
You may also be interested in...
Expert: FDA’s Highly Anticipated PCCP Guidance Isn’t Anything Too ‘Surprising’
The FDA’s highly anticipated predetermined chance control plan (PCCP) guidance document is pretty much what the industry expected, Sidley Austin partner Deeona Gaskin told Medtech Insight.
GAO/NAS Report On AI In Health Care Critical Of FDA Slowness On SaMD Rulemaking
A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.
HHS Advances AI Priorities In Budget Ask
The US Department of Health and Human Services is asking Congress for $10m in its latest budget request specifically to advance the use of artificial intelligence to regulate FDA products and promote development of AI technology. The ask aligns with President Trump’s vision for government agencies to help make the US a leader in AI and machine learning products.